Blood levels alone cannot confirm safe testosterone dosing. Asking about androgenic effects and allowing months for response are central to care.
|Articles|August 18, 2006
Current Options for the Treatment of Symptomatic Uterine Fibroids Video
Author(s)Charles Miller, MD
From the 34th Annual Meeting - Chicago, Illinois - November 2005
Advertisement
The file you requested will begin playing automatically. If it does not, press the 'play' button. If you experience playback problems, make certain you have the latest version of Windows Media Player, available
Advertisement
Related to this article
A global consensus defines what the evidence supports for testosterone in women. Benefits for strength, mood, and cognition lack randomized data.
A testosterone patch improved sexual desire in trials but never won US approval. Normal female physiology defines what replacement should target.
The WHI never studied testosterone, yet it chilled conversations about every hormone, with lasting consequences for women’s sexual health.
As estrogen came to define menopause care, testosterone faded from view, and the oral combination clinicians relied on was never FDA approved.
Androgen therapy for women predates the headlines by decades. Early research showed promise for desire, but long-term safety data never caught up.
Liudmila Zhaunova on a global Flo app study linking higher physical activity to lower perimenopause symptom burden.
The 16-item Perimenopause Symptom Scale showed strong reliability and validity among 1255 women aged 35 to 59 years in the United States.
Advertisement
Advertisement
Trending on Contemporary OB/GYN
1
What biomarker-guided preeclampsia care could look like
2
Testosterone for women: Global consensus and physiologic dosing
3
Comparing VMS Therapy Effects on Menopausal Sleep
4
Testosterone physiology in women and the long road to approval
5